Kasim Kutay

Kasim Kutay
Born (1965-05-13) 13 May 1965
Alexandria, Egypt
CitizenshipBritish
EducationLondon School of Economics (BSc, MSc)
EmployerMorgan Stanley (1989–2007)

Sun Group (2007–2009) Moelis & Company (2009–2016)

Novo Holdings A/S (2016–present)
Title
Board member of
SpouseMaha Arakji
Children3

Kasim Kutay (born 13 May 1965) is a British fund manager who is the CEO of Danish Novo Holdings A/S, an investment company that manages the assets of the Novo Nordisk Foundation. He holds British citizenship and resides in Denmark.

Kutay was an investment banker, focusing on the healthcare sector.[1] He assumed the role of CEO at Novo Holdings A/S in September 2016, following the departure of Eivind Kolding.[2][3][4] Kutay joined Novo after more than two decades working in investment banking.

Early life

Kutay was born in Alexandria, Egypt, on 13 May 1965 to a Turkish father and Syrian mother.[3]

The family moved to Lebanon and remained there until the Lebanese Civil War broke out in 1975, when they relocated to London, United Kingdom.[3]

Kutay attended the American Community School in London.[3] He studied at the London School of Economics and Political Science (LSE), where he earned a BSc in economics and an MSc in politics of the world economy.[5]

Career

Investment banking

Kutay began his career as a graduate trainee at Morgan Stanley in 1989,[3] and spent 18 years there advising mainly healthcare companies.[6] He rose to chairman of its European healthcare group.[4]

Kutay then worked at the US investment firm Sun Group,[3] before joining Moelis & Company in 2009. He worked at Moelis for seven years as co-head of Europe and a member of its management committee.[7][1]

Novo Holdings

Kutay was appointed CEO of Novo Holdings A/S in June 2016, succeeding Eivind Kolding, and took up the role in September 2016.[2] Before becoming CEO, he had advised Novo for a number of years on disposals and acquisitions, as well as other Danish healthcare companies including William Demant and Lundbeck.[2]

Novo Holdings had total assets under management of DKK 694 billion (approximately US$109 billion) as of year-end 2025.[8]

Board memberships and affiliations

  • Kutay is a member of the board of directors of Novo Nordisk A/S and Novonesis (formerly Novozymes).[9][10]
  • He served on the supervisory board of Evotec SE from 2020 until his resignation in June 2022,[11] and was a non-executive director of Convatec from 2017 to July 2018.[12]
  • Kutay is co-chair of the development board of the Chelsea and Westminster NHS Foundation Trust.[3]

Public advocacy and commentary

  • Kutay has written on the need for greater investment and policy measures to address antimicrobial resistance. In a 2020 opinion article co-authored with Eli Lilly chief executive David Ricks, he argued for changes to the market for antibiotics.[13] In 2018, Novo Holdings established the REPAIR Impact Fund, a US$165 million fund focused on companies researching new antibiotics.[14]
  • Kutay has also advocated for wider adoption of biotechnology in industry and agriculture as part of the green transition, and for faster bioindustrial approval processes in Europe.[15][16]
  • He has written on the role of capital markets in supporting a "stakeholder" model of corporate governance, including restraints on certain hostile mergers and acquisitions.[17]
  • Kutay has supported the launch of Best For You, a model of care for adolescent mental health based at Chelsea and Westminster Hospital.[18]

Awards and honours

Personal life

Kutay resides in Denmark and is married to architect Maha Arakji Kutay.[3] They have three children.[3]

References

  1. 1 2 "Archived copy" (PDF). Archived from the original (PDF) on 6 March 2017. Retrieved 5 March 2017.{{cite web}}: CS1 maint: archived copy as title (link)
  2. 1 2 3 "Investment firm Novo names Moelis's Kutay as new chief executive". Bloomberg.com. 21 June 2016. Retrieved 12 January 2022.
  3. 1 2 3 4 5 6 7 8 9 Meddings, Sabah (4 November 2018). "Interview: biotech boss Kasim Kutay is investing billions – according to Jante". The Sunday Times. ISSN 0956-1382. Retrieved 10 December 2018.
  4. 1 2 "After ousting former CEO, Novo A/S puts Kutay in charge of $57B investment vehicle". Fiercebiotech.com. 22 June 2016. Retrieved 5 March 2017.
  5. ↑ "Due Diligence Live Agenda – A FT Live Event". duediligence.live.ft.com. Retrieved 14 May 2025.
  6. ↑ "Kasim Kutay: Executive Profile & Biography – Bloomberg". Bloomberg News. Retrieved 5 March 2017.
  7. ↑ "Novo A/S appoints new CEO". PharmaTimes. 21 June 2016.
  8. ↑ Novo Holdings (2026). Annual Report 2025 (PDF) (Report). Retrieved 30 June 2026.
  9. ↑ "Kasim Kutay". novonordisk.com. Novo Nordisk. Retrieved 30 June 2026.
  10. ↑ "Meet our leadership team". novonesis.com. Novonesis. Retrieved 30 June 2026.
  11. ↑ "Evotec SE reports results of Annual General Meeting 2022" (Press release). Evotec SE. 22 June 2022. Retrieved 30 June 2026.
  12. ↑ "Proposed directorate changes". Convatec Group. Retrieved 12 January 2022.
  13. ↑ Ricks, David A.; Kutay, Kasim (8 July 2020). "Opinion: A Plan to Avert a 'Superbug' Pandemic". The Wall Street Journal. Retrieved 12 January 2022.
  14. ↑ "Novo Holdings launches USD 165m impact fund to combat antimicrobial resistance" (Press release). Novo Holdings. 28 February 2018. Retrieved 12 January 2022.
  15. ↑ "Novo Holdings sets sights on more acquisitions in hot bioindustry sector". MedWatch.
  16. ↑ "Biosolutions: a clear path to fighting climate change". World Economic Forum. 23 May 2022.
  17. ↑ "Kasim Kutay". The Daily Telegraph. Retrieved 12 January 2022.
  18. ↑ "Best For You". cwplus.org.uk. 15 December 2020. Retrieved 12 January 2022.
  19. ↑ "Prominent leaders from Novo Nordisk Foundation and Novo Holdings honoured with the Business Award of the Year 2025" (Press release) (in Danish). PwC Denmark. Retrieved 30 June 2026.
  20. ↑ "Modtagere af danske dekorationer". kongehuset.dk (in Danish). Retrieved 26 June 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.